Company intelligence
CHARM Therapeutics
Protein-ligand intelligence to deliver next generation small molecule therapeutics
Biotechnology Research
London, GB
30 employees
Founded 2021
1 public signals
About CHARM Therapeutics
CHARM's lead program is a next-generation menin inhibitor for the treatment of acute myeloid leukemia (AML). Unlike first-generation menin inhibitors that rapidly lose potency due to menin resistance mutations, CHARM's candidates are specifically designed to maintain potency against all known clinical resistance mutations, potentially delivering the durable responses that patients desperately need.
Verified activity
Signals from CHARM Therapeutics
1 published signal